[225Ac]Ac‐PSMA for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis

前列腺癌 医学 荟萃分析 阉割 肿瘤科 癌症 内科学 激素
作者
Maria Luisa Garo,Petra Petranović Ovčariček,Stefano Fanti,Luca Giovanella
出处
期刊:European Journal of Clinical Investigation [Wiley]
卷期号:55 (5): e14358-e14358 被引量:13
标识
DOI:10.1111/eci.14358
摘要

Abstract Background Approximately 10%–20% of prostate cancers progress to metastatic and castration‐resistant forms (mCRPC). Radioligand (RLT) therapy with [177Lu]Lu‐prostate‐specific membrane antigen (PSMA) is an approved treatment for metastasized mCRPC. Moreover, Actinium‐225 (225Ac), an alpha‐emitter isotope, has also been used to label PSMA and, recently, to treat mCRPC patients with encouraging results. However, robust clinical data on [225Ac]Ac‐PSMA therapy and its comparison with [177Lu]Lu‐PSMA are still limited. Our aim was to evaluate the role of [225Ac]Ac‐PSMA in treating mCRPC and compare it with conventional [177Lu]Lu‐PSMA therapy. Methods A systematic search was performed in PubMed, Web of Science, Scopus and the Cochrane Register of Controlled Trials from June 2023 to January 2024. This work was conducted in accordance with PRISMA guidelines. Results After screening and study selection according to PRISMA guidelines, 11 studies were included, 9 of which focused on [225Ac]Ac‐PSMA only and two on tandem therapy ([225Ac]Ac‐PSMA/[177Lu]Lu‐PSMA). Overall, the pooled proportion of PSA decline in patients was .85 (95% CI: .79–.91, p < .001); patients pretreated with [177Lu]Lu‐PSMA achieved a pooled proportion of PSA decline of .90 (95% CI: .82–.97, p < .001). In patients treated with tandem therapy, PSA decline was observed in approximately 90% of them, while PSA response rates above 50% ranged from 53.3% to 65%. Xerostomia was the most frequently reported side effect, along with anaemia, thrombocytopenia and nephrotoxicity. Conclusions Overall, the main results of our study showed that [225Ac]Ac‐PSMA‐617 had a significant therapeutic effect on mCRPC with an acceptable toxicity level. The latter, however, appears greater than with [177Lu]Lu‐PSMA‐617. In future studies, an adequate analysis of the incidence of side effects associated with [225Ac]Ac‐PSMA should be performed to evaluate the role of cumulative toxicity of earlier treatments and the higher frailty of heavily pretreated patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
焯爱睡觉完成签到,获得积分10
刚刚
NLANDLV完成签到,获得积分10
刚刚
Criminology34的应助被安静的季节采纳,获得10
1秒前
Criminology34的应助被安静的季节采纳,获得10
1秒前
追寻蜗牛完成签到,获得积分10
1秒前
1秒前
隐形曼青的应助被史聪聪采纳,获得30
2秒前
2秒前
3秒前
卢帅完成签到,获得积分20
3秒前
3秒前
pink婷完成签到 ,获得积分10
3秒前
任性子骞完成签到,获得积分10
5秒前
慕青的应助被小涵采纳,获得10
5秒前
6秒前
米豆完成签到 ,获得积分10
6秒前
猪猪hero的应助被优雅的曲奇饼采纳,获得10
6秒前
归宁完成签到,获得积分10
6秒前
旧年完成签到 ,获得积分10
7秒前
chan发布了新的文献求助10
8秒前
温暖的绮彤完成签到 ,获得积分10
8秒前
kk发布了新的文献求助10
9秒前
Lin发布了新的文献求助10
10秒前
清蒸青衣鱼完成签到,获得积分10
10秒前
蔼看文献发布了新的文献求助10
11秒前
Orange的应助被沉默的咖啡豆采纳,获得10
12秒前
靓丽醉蝶的应助被隐无名采纳,获得10
13秒前
layzhj完成签到,获得积分10
13秒前
14秒前
寒耒完成签到,获得积分10
15秒前
15秒前
weifengzhong发布了新的文献求助10
15秒前
16秒前
负责平蝶完成签到,获得积分10
16秒前
孙某人发布了新的文献求助30
17秒前
17秒前
17秒前
激动的项链完成签到,获得积分10
17秒前
想要吉姆尼完成签到,获得积分10
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211